Eleni Andreopoulou

4.2k total citations
90 papers, 2.2k citations indexed

About

Eleni Andreopoulou is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eleni Andreopoulou has authored 90 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 34 papers in Cancer Research and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eleni Andreopoulou's work include Cancer Cells and Metastasis (19 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (14 papers). Eleni Andreopoulou is often cited by papers focused on Cancer Cells and Metastasis (19 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (14 papers). Eleni Andreopoulou collaborates with scholars based in United States, Italy and Greece. Eleni Andreopoulou's co-authors include Massimo Cristofanilli, Vicente Valero, James M. Reuben, Joseph A. Sparano, Naoto T. Ueno, Hayley M. McDaid, Julian A. Smith, Beverly C. Handy, Savitri Krishnamurthy and Herbert A. Fritsche and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eleni Andreopoulou

86 papers receiving 2.1k citations

Peers

Countries citing papers authored by Eleni Andreopoulou

Since Specialization

Citations

This map shows the geographic impact of Eleni Andreopoulou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleni Andreopoulou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleni Andreopoulou more than expected).

Fields of papers citing papers by Eleni Andreopoulou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleni Andreopoulou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleni Andreopoulou. The network helps show where Eleni Andreopoulou may publish in the future.

Co-authorship network of co-authors of Eleni Andreopoulou

This figure shows the co-authorship network connecting the top 25 collaborators of Eleni Andreopoulou. A scholar is included among the top collaborators of Eleni Andreopoulou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleni Andreopoulou. Eleni Andreopoulou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study 2021 ·Clinical Cancer Research ·Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou, Debra A. Patt, Yuan Yuan, Grace Wang, (unknown), Dongyuan Xing, (unknown), Vassiliki Karantza, Sami Diab	90
2	Alterations of the 70 kDa heat shock protein (HSP70) and sequestosome-1 (p62) in women with breast cancer 2021 ·Scientific Reports ·Theofano Orfanelli, Spyridon Giannopoulos, Eleni Zografos, Aikaterini Athanasiou, Ann Marie Bongiovanni, Georgios Doulaveris, (unknown), (unknown), Chris Bakoyiannis, Georgios Théodoropoulos, Georgios Zografos, Eleni Andreopoulou, Steven S. Witkin	5
3	Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer 2021 ·npj Breast Cancer ·Ying L. Liu, Cecilie L. Bager, Nicholas Willumsen, Divya Ramchandani, Naomi Kornhauser, Ling Lu, Marta Vallee Cobham, Eleni Andreopoulou, Tessa Cigler, Anne Moore, (unknown), Veronica Fitzpatrick, Maureen M. Ward, J. David Warren, Claudia Fischbach, Vivek Mittal, Linda T. Vahdat	58
4	Endocrine Therapy-related Endocrinopathies—Biology, Prevalence, and Implications for the Management of Breast Cancer 2020 ·PubMed ·Kristy A. Brown, Eleni Andreopoulou, Panagiota Andreopoulou	3
5	Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer 2020 ·Frontiers in Oncology ·Douglas K. Marks, Robyn D. Gartrell, Margueritta El Asmar, (unknown), Thomas D. Hart, Yan Lu, Qingfei Pan, Jiyang Yu, Hanina Hibshoosh, Hua Guo, Eleni Andreopoulou, Lisa Wiechmann, Katherine D. Crew, Joseph A. Sparano, Dawn L. Hershman, Eileen P. Connolly, Yvonne M. Saenger, Kevin Kalinsky	20
6	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy 2018 ·Annals of Oncology ·(unknown), Roberto Salgado, Maria Vittoria Dieci, Andrea Vingiani, Giuseppe Curigliano, Rebekah Gould, Carlos A. Castañeda, Timothy M. D’Alfonso, Joselyn Sanchez, Esther Cheng, Eleni Andreopoulou, Miluska Castillo, Sylvia Adams, Sandra Demaria, W. Fraser Symmans, Stefan Michiels, Sherene Loi	119
7	Therapeutic Advances and New Directions for Triple-Negative Breast Cancer 2017 ·Breast Care ·Eleni Andreopoulou, Catherine M. Kelly, Hayley M. McDaid	33
8	Is Race a Prognostically Significant Factor in Survival Outcomes for Breast Cancer Among Caucasian and African-American Women? 2016 ·(unknown), Eleni Andreopoulou, (unknown)	1
9	A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer 2014 ·Breast Cancer Research and Treatment ·Yifan Tu, Dawn L. Hershman, Kapil N. Bhalla, Warren Fiskus, Christine Pellegrino, Eleni Andreopoulou, Della Makower, Kevin Kalinsky, Karen Fehn, Susan Fineberg, Abdissa Negassa, Leslie L. Montgomery, Lisa Wiechmann, R. Katherine Alpaugh, Min Huang, Joseph A. Sparano	51
10	Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma 2013 ·Breast Cancer Research and Treatment ·Eleni Andreopoulou, (unknown), Vicente Valero, Dawn L. Hershman, George Raptis, Linda T. Vahdat, Hyo S. Han, James R. Wright, Christine Pellegrino, Massimo Cristofanilli, Ricardo H. Álvarez, Karen Fehn, Susan Fineberg, Joseph A. Sparano	15
11	Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? 2011 ·Annals of Oncology ·Catherine M. Kelly, Kathleen I. Pritchard, Maureen Trudeau, Eleni Andreopoulou, Kenneth R. Hess, Lajos Pusztai	20
12	Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy 2011 ·Annals of Oncology ·Antonio Giordano, Mario Giuliano, Michelino De Laurentiis, Grazia Arpino, Summer Jackson, Beverly C. Handy, Naoto T. Ueno, Eleni Andreopoulou, (unknown), Vicente Valero, Sabino De Placido, Gabriel N. Hortobágyi, James M. Reuben, Massimo Cristofanilli	85
13	Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer 2010 ·Cancer Chemotherapy and Pharmacology ·Eleni Andreopoulou, Tai C. Chen, Leonard Liebes, John P. Curtin, Stephanie V. Blank, Robert C. Wallach, Howard S. Höchster, Franco M. Muggia	9
14	Comparison of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaTest breast cancer for detection and biological characterization 2008 ·Clinical Cancer Research ·Eleni Andreopoulou, Diana L. Urbauer, Savitri Krishnamurthy, James M. Reuben, Vicente Valero, Massimo Cristofanilli, Herbert A. Fritsche	2
15	Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer 2007 ·Annals of Oncology ·Eleni Andreopoulou, (unknown), (unknown), (unknown), D. Mirchandani, A. Hamilton, Allan J. Jacobs, John P. Curtin, Franco M. Muggia	58
16	Treatment of Uterine Sarcoma at the Royal Marsden Hospital from 1974 to 1998 2004 ·Clinical Oncology ·Lorenzo Livi, Eleni Andreopoulou, N.G. Shah, Fabiola Paiar, (unknown), Ian Judson, Clive Harmer	26
17	The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma 2004 ·Annals of Oncology ·Eleni Andreopoulou, Paul J. Ross, Mary O’Brien, Hugo Ford, K. Priest, Tim Eisen, A. Norton, S. Ashley, Ian E. Smith	33
18	Favorable Outcome of Ovarian Germ Cell Malignancies Treated with Cisplatin or Carboplatin-Based Chemotherapy: A Hellenic Cooperative Oncology Group Study 1998 ·Gynecologic Oncology ·Meletios Α. Dimopoulos, Maria V. Papadopoulou, Eleni Andreopoulou, (unknown), Nicholas Pavlidis, Gerasimos Aravantinos, (unknown), Αchilles Anagnostopoulos, George Fountzilas, S. Michalas, (unknown)	33
19	A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study 1997 ·Annals of Oncology ·George Fountzilas, A. Athanassiades, T. Giannakakis, Evangelos Briasoulis, Dimitrios Bafaloukos, Anna Kalogera‐Fountzila, (unknown), Haralabos P. Kalofonos, D. Pectasides, Eleni Andreopoulou, C. Bamia, P. Kosmidis, Nicholas Pavlidis, Dimosthenis Skarlos	28
20	Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study 1997 ·Annals of Oncology ·P. Kosmidis, N. Mylonakis, George Fountzilas, Epaminontas Samantas, A. Athanasiadis, Eleni Andreopoulou, N. Pavlidis, D. Skarlos	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact